Table 1.
Characteristics of the cohort included in this study
| Total (n = 18) | Paired data (n = 15) | |
|---|---|---|
| General characteristics | ||
| Male gender | 17 (94%) | 14 (93%) |
| Age (yr) | 67 (59–74) | 71 (64–75) |
| BMI (kg/m2) | 26.2 (23.2–30.7) | 24.7 (22.6–30.6) |
| NYHA I | 4 (22%) | 4 (27%) |
| NYHA II | 8 (44%) | 7 (46%) |
| NYHA III | 6 (33%) | 4 (27%) |
| Comorbidities | ||
| Ischemic cardiomyopathy | 9 (50%) | 6 (40%) |
| Medication | ||
| Beta blockers | 17 (94%) | 14 (93%) |
| ACE-inhibitors/Angiotensin II receptor blockers | 18 (100%) | 15 (100%) |
| Diuretics | 14 (78%) | 12 (80%) |
| Aldosterone antagonists | 7 (39%) | 5 (33%) |
| ECG characteristics | ||
| Sinus rhythm | 18 (100%) | 15 (100%) |
| QRS duration (ms) | 131 ± 30.1 | 129 ± 29 |
| QRS duration ≥ 130 (ms) | 10 (56%) | 8 (53%) |
| LBBB | 8 (44%) | 6 (40%) |
| Lab results | ||
| NT-proBNP (pmol/l) | 125 (67–205) | 125 (67–205) |
| Echocardiography | ||
| End-diastolic volume (ml) | 174 (148–231) | 171 (144–225) |
| End-systolic volume (ml) | 124 (96.4–177) | 121 (96–173) |
| Ejection fraction (%) | 28.6 (26.5–33.1) | 29.0 (24.3–33.3) |
BMI body mass index, NYHA New York Heart Association, ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blockers, ECG electrocardiogram, LBBB left bundle branch block, NT-proBNP N-terminal prohormone of brain natriuretic peptide